To evaluate the Safety and Efficacy of HIPEC Combined With Sintilimab for Gastric Cancer Patients with Peritoneal Metastasis.
Advanced gastric (gastroesophageal junction) adenocarcinoma confirmed by histology;
Age 18-75 years, Male or Non pregnant female
ECOG (Eastern Cooperative Oncology Group) : 0~1；
Negative for HER-2 by IHC/FISH；
Other distal metastases besides peritoneal metastases (e.g., liver, lung, pleural, brain, bone metastases, etc.);
Previous systemic therapy for gastric cancer;
Recurrent gastric cancer after surgery;
Cardiopulmonary dysfunction;